78 related articles for article (PubMed ID: 18381964)
21. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
22. N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Raeppel S; Claridge S; Saavedra O; Gaudette F; Zhan L; Mannion M; Zhou N; Raeppel F; Granger MC; Isakovic L; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman J; Vaisburg A
Bioorg Med Chem Lett; 2009 Mar; 19(5):1323-8. PubMed ID: 19211249
[TBL] [Abstract][Full Text] [Related]
23. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
24. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Takeuchi K; Shin-ya T; Nishio K; Ito F
FEBS J; 2009 Mar; 276(5):1255-65. PubMed ID: 19175673
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
[TBL] [Abstract][Full Text] [Related]
27. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
[TBL] [Abstract][Full Text] [Related]
28. Targeting the MET oncogene in cancer and metastases.
Stella GM; Benvenuti S; Comoglio PM
Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
[TBL] [Abstract][Full Text] [Related]
29. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
30. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
31. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
Medicherla S; Reddy M; Ying J; Navas TA; Li L; Nguyen AN; Kerr I; Hanjarappa N; Protter AA; Higgins LS
Anticancer Res; 2008; 28(6A):3827-33. PubMed ID: 19189670
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway.
Mak HH; Peschard P; Lin T; Naujokas MA; Zuo D; Park M
Oncogene; 2007 Nov; 26(51):7213-21. PubMed ID: 17533376
[TBL] [Abstract][Full Text] [Related]
33. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.
Graveel C; Su Y; Koeman J; Wang LM; Tessarollo L; Fiscella M; Birchmeier C; Swiatek P; Bronson R; Vande Woude G
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17198-203. PubMed ID: 15557554
[TBL] [Abstract][Full Text] [Related]
34. Transgenic mice as an in vivo model of lymphomagenesis.
Tarantul VZ
Int Rev Cytol; 2004; 236():123-80. PubMed ID: 15261738
[TBL] [Abstract][Full Text] [Related]
35. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.
Torti D; Sassi F; Galimi F; Gastaldi S; Perera T; Comoglio PM; Trusolino L; Bertotti A
Int J Cancer; 2012 Mar; 130(6):1357-66. PubMed ID: 21500189
[TBL] [Abstract][Full Text] [Related]
36. Novel interaction partners of the TPR/MET tyrosine kinase.
Schaaf CP; Benzing J; Schmitt T; Erz DH; Tewes M; Bartram CR; Janssen JW
FASEB J; 2005 Feb; 19(2):267-9. PubMed ID: 15546961
[TBL] [Abstract][Full Text] [Related]
37. Tumor growth need not be driven by rare cancer stem cells.
Kelly PN; Dakic A; Adams JM; Nutt SL; Strasser A
Science; 2007 Jul; 317(5836):337. PubMed ID: 17641192
[TBL] [Abstract][Full Text] [Related]
38. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
Smolen GA; Sordella R; Muir B; Mohapatra G; Barmettler A; Archibald H; Kim WJ; Okimoto RA; Bell DW; Sgroi DC; Christensen JG; Settleman J; Haber DA
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2316-21. PubMed ID: 16461907
[TBL] [Abstract][Full Text] [Related]
39. The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F; Chung EYL; Gaudio E; Tarantelli C; Cascione L; Napoli S; Jessen K; Carrassa L; Priebe V; Sartori G; Graham G; Selvanathan SP; Cavalli A; Rinaldi A; Kwee I; Testoni M; Genini D; Ye BH; Zucca E; Stathis A; Lannutti B; Toretsky JA; Bertoni F
Clin Cancer Res; 2019 Aug; 25(16):5167-5176. PubMed ID: 31182435
[TBL] [Abstract][Full Text] [Related]
40. A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart.
Sala V; Gatti S; Gallo S; Medico E; Cantarella D; Cimino J; Ponzetto A; Crepaldi T
Biomed Res Int; 2016; 2016():9549036. PubMed ID: 27298830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
